|
US7045313B1
(en)
|
1982-11-30 |
2006-05-16 |
The United States Of America As Represented By The Department Of Health And Human Services |
Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA
|
|
US5168062A
(en)
|
1985-01-30 |
1992-12-01 |
University Of Iowa Research Foundation |
Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
|
|
US4751180A
(en)
|
1985-03-28 |
1988-06-14 |
Chiron Corporation |
Expression using fused genes providing for protein product
|
|
US4935233A
(en)
|
1985-12-02 |
1990-06-19 |
G. D. Searle And Company |
Covalently linked polypeptide cell modulators
|
|
IL85035A0
(en)
|
1987-01-08 |
1988-06-30 |
Int Genetic Eng |
Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
|
|
WO1988007089A1
(en)
|
1987-03-18 |
1988-09-22 |
Medical Research Council |
Altered antibodies
|
|
US5443964A
(en)
|
1987-08-10 |
1995-08-22 |
Duke University |
Poxvirus insertion/expression vector
|
|
US5283173A
(en)
|
1990-01-24 |
1994-02-01 |
The Research Foundation Of State University Of New York |
System to detect protein-protein interactions
|
|
US6410010B1
(en)
|
1992-10-13 |
2002-06-25 |
Board Of Regents, The University Of Texas System |
Recombinant P53 adenovirus compositions
|
|
DK0584266T3
(da)
|
1991-05-06 |
2003-12-29 |
Us Gov Health & Human Serv |
Rekombinant virus udtrykkende carcinoembryonalt antigen og fremgangsmåder til anvendelse heraf
|
|
EP1400536A1
(en)
|
1991-06-14 |
2004-03-24 |
Genentech Inc. |
Method for making humanized antibodies
|
|
US5262522A
(en)
|
1991-11-22 |
1993-11-16 |
Immunex Corporation |
Receptor for oncostatin M and leukemia inhibitory factor
|
|
AU691811B2
(en)
|
1993-06-16 |
1998-05-28 |
Celltech Therapeutics Limited |
Antibodies
|
|
US5457035A
(en)
|
1993-07-23 |
1995-10-10 |
Immunex Corporation |
Cytokine which is a ligand for OX40
|
|
JP4418965B2
(ja)
|
1994-09-23 |
2010-02-24 |
タップイミューン・インコーポレイテッド |
内在性ペプチドを有するｍｈｃクラスｉ分子の発現を増強する方法
|
|
JP3907698B2
(ja)
|
1994-10-03 |
2007-04-18 |
アメリカ合衆国 |
抗原を発現する組み換えウイルスと免疫刺激分子を発現する組み換えウイルスとを含む組成物
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
US5641870A
(en)
|
1995-04-20 |
1997-06-24 |
Genentech, Inc. |
Low pH hydrophobic interaction chromatography for antibody purification
|
|
ES2248823T5
(es)
|
1996-10-25 |
2011-11-03 |
Human Genome Sciences, Inc. |
Neutroquina alfa.
|
|
US5969102A
(en)
|
1997-03-03 |
1999-10-19 |
St. Jude Children's Research Hospital |
Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof
|
|
JP4213224B2
(ja)
|
1997-05-02 |
2009-01-21 |
ジェネンテック，インコーポレーテッド |
ヘテロマルチマー及び共通成分を有する多重特異性抗体の製造方法
|
|
GB9801930D0
(en)
|
1998-01-29 |
1998-03-25 |
Univ London |
Mutant herpes simplex viruses and uses thereof
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
ES2292236T3
(es)
|
1998-04-02 |
2008-03-01 |
Genentech, Inc. |
Variantes de anticuerpos y sus fragmentos.
|
|
GB2337755B
(en)
|
1998-05-29 |
2003-10-29 |
Secr Defence |
Virus vaccine
|
|
DK2272859T3
(en)
|
1998-08-07 |
2015-01-19 |
Univ Washington |
Immunological herpes simplex virus antigens and methods for their use
|
|
US20060067933A1
(en)
|
1999-01-07 |
2006-03-30 |
Gross Jane A |
Soluble receptor BR43x2 and methods of using
|
|
DE60043626D1
(de)
|
1999-01-07 |
2010-02-11 |
Zymogenetics Inc |
Verfahren zur therapeutischen Verwendung von löslichen rezeptoren BR43X2
|
|
US7833529B1
(en)
*
|
1999-01-07 |
2010-11-16 |
Zymogenetics, Inc. |
Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
|
|
HU230769B1
(hu)
|
1999-01-15 |
2018-03-28 |
Genentech Inc. |
Módosított effektor-funkciójú polipeptid-változatok
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
US20030095967A1
(en)
|
1999-01-25 |
2003-05-22 |
Mackay Fabienne |
BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
|
|
US20030022233A1
(en)
|
1999-04-30 |
2003-01-30 |
Raymond G. Goodwin |
Methods of use of the taci/taci-l interaction
|
|
PT1916258E
(pt)
|
1999-08-09 |
2014-07-29 |
Genzyme Corp |
Aumento da expressão de uma sequência nucleotídica heteróloga de cadeia simples a partir de vectores virais recombinantes por concepção da sequência de maneira que esta forme pares de bases intracadeia
|
|
US7329728B1
(en)
|
1999-10-25 |
2008-02-12 |
The Scripps Research Institute |
Ligand activated transcriptional regulator proteins
|
|
CA2396793A1
(en)
|
2000-02-16 |
2001-08-23 |
Genentech, Inc. |
Uses of agonists and antagonists to modulate activity of tnf-related molecules
|
|
US20040013674A1
(en)
|
2001-04-27 |
2004-01-22 |
Christine Ambrose |
Taci as an anti-tumor agent
|
|
JP2004513876A
(ja)
|
2000-04-27 |
2004-05-13 |
バイオジェン インコーポレーテッド |
抗−腫瘍剤としてのｔａｃｉ
|
|
EP1746106A3
(en)
|
2000-04-27 |
2007-03-14 |
Biogen Idec MA Inc. |
Use of TACI as an anti-tumor agent
|
|
US20020086018A1
(en)
|
2000-05-12 |
2002-07-04 |
Theill Lars Eyde |
Methods and compositions of matter concerning APRIL/G70, BCMA, BLYS/AGP-3, and TACI
|
|
CA2413160A1
(en)
|
2000-06-15 |
2001-12-20 |
Human Genome Sciences, Inc. |
Human tumor necrosis factor delta and epsilon
|
|
AU2001268427B2
(en)
|
2000-06-16 |
2007-03-29 |
Glaxosmithkline Intellectual Property Limited |
Antibodies that immunospecifically bind to blys
|
|
US7879328B2
(en)
|
2000-06-16 |
2011-02-01 |
Human Genome Sciences, Inc. |
Antibodies that immunospecifically bind to B lymphocyte stimulator
|
|
US7220840B2
(en)
|
2000-06-16 |
2007-05-22 |
Human Genome Sciences, Inc. |
Antibodies that immunospecifically bind to B lymphocyte stimulator protein
|
|
CA2411828A1
(en)
|
2000-06-23 |
2002-01-03 |
Maxygen, Inc. |
Novel co-stimulatory molecules
|
|
US20030012783A1
(en)
|
2001-02-20 |
2003-01-16 |
Wayne Kindsvogel |
Antibodies that bind both BCMA and TACI
|
|
JP2004537290A
(ja)
|
2001-05-24 |
2004-12-16 |
ヒューマン ジノーム サイエンシーズ， インコーポレイテッド |
腫瘍壊死因子δ（ＡＰＲＩＬ）に対する抗体
|
|
BRPI0209933B8
(pt)
|
2001-05-24 |
2021-05-25 |
Zymogenetics Inc |
proteína de fusão, e, molécula de ácido nucleico
|
|
BR0211614A
(pt)
|
2001-08-03 |
2006-10-31 |
Genentech Inc |
polipeptìdeo tacis e br3 e empregos dos mesmos
|
|
EP1456347A4
(en)
|
2001-11-16 |
2006-08-02 |
Human Genome Sciences Inc |
IMMUNE SPECIFIC TO BLYS BINDING ANTIBODIES
|
|
US7247615B2
(en)
|
2001-11-30 |
2007-07-24 |
United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Peptide agonists of prostate-specific antigen and uses therefor
|
|
US8188231B2
(en)
|
2002-09-27 |
2012-05-29 |
Xencor, Inc. |
Optimized FC variants
|
|
CN1692127A
(zh)
|
2002-07-25 |
2005-11-02 |
健泰科生物技术公司 |
Taci抗体及其用途
|
|
EP1558278B1
(en)
|
2002-10-11 |
2009-09-02 |
ZymoGenetics, Inc. |
Production of homotrimeric fusion proteins
|
|
US7361740B2
(en)
|
2002-10-15 |
2008-04-22 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
|
EP3263596A1
(en)
|
2002-12-16 |
2018-01-03 |
Genentech, Inc. |
Immunoglobulin variants and uses thereof
|
|
AU2003299971A1
(en)
|
2002-12-30 |
2004-07-29 |
Amgen Inc. |
Combination therapy with co-stimulatory factors
|
|
US20050163775A1
(en)
|
2003-06-05 |
2005-07-28 |
Genentech, Inc. |
Combination therapy for B cell disorders
|
|
PL1631313T3
(pl)
|
2003-06-05 |
2015-08-31 |
Genentech Inc |
Terapia skojarzona zaburzeń z komórek B
|
|
AU2004285455A1
(en)
|
2003-10-20 |
2005-05-12 |
Biogen Idec Ma Inc. |
Therapeutic regimens for BAFF antagonists
|
|
KR100956913B1
(ko)
|
2003-12-19 |
2010-05-11 |
제넨테크, 인크. |
치료제로서 유용한 일가 항체 단편
|
|
KR100891620B1
(ko)
|
2004-04-13 |
2009-04-02 |
에프. 호프만-라 로슈 아게 |
항-ｐ-셀렉틴 항체
|
|
CN103172731A
(zh)
|
2004-07-15 |
2013-06-26 |
赞科股份有限公司 |
优化的Fc变体
|
|
TWI309240B
(en)
|
2004-09-17 |
2009-05-01 |
Hoffmann La Roche |
Anti-ox40l antibodies
|
|
US8911726B2
(en)
|
2004-09-22 |
2014-12-16 |
Kyowa Hakko Kirin Co., Ltd |
Stabilized human Igg4 antibodies
|
|
CA2585927A1
(en)
|
2004-11-04 |
2006-05-18 |
Genentech, Inc. |
Polypeptides that bind baff and/or april
|
|
WO2006060314A2
(en)
|
2004-12-01 |
2006-06-08 |
Bayer Schering Pharma Aktiengesellschaft |
Generation of replication competent viruses for therapeutic use
|
|
BRPI0518994A2
(pt)
|
2004-12-31 |
2008-12-02 |
Biogen Idec Inc |
anticorpos ou polipeptÍdeos que se ligam a br3, seus usos e formulaÇÕes lÍquidas
|
|
EP3050963B1
(en)
|
2005-03-31 |
2019-09-18 |
Chugai Seiyaku Kabushiki Kaisha |
Process for production of polypeptide by regulation of assembly
|
|
CN104356236B
(zh)
|
2005-07-01 |
2020-07-03 |
E.R.施贵宝&圣斯有限责任公司 |
抗程序性死亡配体1(pd-l1)的人单克隆抗体
|
|
EP1922079A2
(en)
|
2005-08-09 |
2008-05-21 |
ZymoGenetics, Inc. |
Methods for the treatment and prevention of abnormal cell proliferation using taci-fusion molecules
|
|
AU2006278229B2
(en)
|
2005-08-09 |
2011-10-27 |
Ares Trading S.A. |
Methods for treating B-cell malignancies using TACI-Ig fusion molecule
|
|
WO2007019618A1
(en)
|
2005-08-12 |
2007-02-22 |
Garvan Institute Of Medical Research |
Phrophylactic and/or therapeutic method for treatment of autoimmune disease
|
|
JP2007103345A
(ja)
|
2005-09-07 |
2007-04-19 |
Toyota Motor Corp |
チューブ状固体高分子型燃料電池、及びチューブ状固体高分子型燃料電池の製造方法
|
|
ES2415890T3
(es)
|
2005-09-09 |
2013-07-29 |
Zymogenetics, Inc. |
Procedimiento de preparación de proteínas triméricas
|
|
US9168286B2
(en)
|
2005-10-13 |
2015-10-27 |
Human Genome Sciences, Inc. |
Methods and compositions for use in treatment of patients with autoantibody positive disease
|
|
EA015860B1
(ru)
|
2005-10-13 |
2011-12-30 |
Хьюман Дженом Сайенсиз, Инк. |
Способы лечения аутоиммунных заболеваний при использовании антагониста нейтрокина-альфа
|
|
US8202698B2
(en)
|
2005-11-08 |
2012-06-19 |
Biogen Idec Ma Inc. |
Methods of evaluating BAFF
|
|
JP2009537563A
(ja)
|
2006-05-15 |
2009-10-29 |
アレス トレーディング ソシエテ アノニム |
Ｔａｃｉ融合分子を使用する自己免疫疾患を治療するための方法
|
|
BRPI0714495B8
(pt)
|
2006-07-21 |
2021-05-25 |
California Inst Of Techn |
lentivírus deficiente para replicação recombinante pseudotipado
|
|
JP2010501622A
(ja)
|
2006-08-28 |
2010-01-21 |
アレス トレーディング ソシエテ アノニム |
Ｆｃ−融合タンパク質の精製法
|
|
EA017733B1
(ru)
|
2006-08-28 |
2013-02-28 |
Арес Трейдинг С.А. |
СПОСОБ ОЧИСТКИ Fc-СЛИТЫХ БЕЛКОВ
|
|
DK2061803T4
(da)
|
2006-08-28 |
2022-12-05 |
Ares Trading Sa |
Fremgangsmåde til oprensning af fc-holdige proteiner
|
|
WO2008092117A2
(en)
|
2007-01-25 |
2008-07-31 |
Xencor, Inc. |
Immunoglobulins with modifications in the fcr binding region
|
|
CA2674213A1
(en)
|
2007-01-26 |
2008-07-31 |
Merck Serono S.A. |
Purification of fc-taci fusion proteins using the oilbody technology
|
|
JP5426531B2
(ja)
|
2007-03-27 |
2014-02-26 |
ザイモジェネティクス， インコーポレイテッド |
自己免疫疾患の治療のためのＢＬｙＳ阻害および／またはＡＰＲＩＬ阻害ならびに免疫抑制剤の組み合わせ
|
|
SG182191A1
(en)
|
2007-06-13 |
2012-07-30 |
Zymogenetics Inc |
Use of taci-ig fusion protein such as atacicept for the manufacture of a medicament for treating lupus erythematosus
|
|
CN101323643B
(zh)
|
2007-06-15 |
2010-12-01 |
烟台荣昌生物工程有限公司 |
优化的TACI-Fc融合蛋白
|
|
ATE502114T1
(de)
|
2007-06-21 |
2011-04-15 |
Univ Muenchen Tech |
Biologisch aktive proteine mit erhöhter in-vivo- und/oder in-vitro-stabilität
|
|
EP2170946A2
(en)
|
2007-07-13 |
2010-04-07 |
The Johns Hopkins University |
B7-dc variants
|
|
EP2200631A1
(en)
|
2007-10-16 |
2010-06-30 |
Zymogenetics, Inc. |
Combination of blys inhibition and anti-cd 20 agents for treatment of autoimmune disease
|
|
CA2701221A1
(en)
|
2007-10-22 |
2009-04-30 |
Merck Serono S.A. |
Method for purifying an fc-containing protein
|
|
WO2009062960A1
(en)
|
2007-11-12 |
2009-05-22 |
Ares Trading S.A. |
Formulations for taci-immunoglobulin fusion proteins
|
|
JP2011503036A
(ja)
|
2007-11-12 |
2011-01-27 |
アレス トレーディング ソシエテ アノニム |
再発性多発性硬化症治療のためのｔａｃｉ−免疫グロブリン融合タンパク質
|
|
WO2009062916A1
(en)
|
2007-11-12 |
2009-05-22 |
Ares Trading S.A. |
Taci-immunoglobulin fusion proteins for treatment of optic neuritis
|
|
RS56844B1
(sr)
|
2007-12-11 |
2018-04-30 |
Univ North Carolina Chapel Hill |
Retrovirusni vektori sa modifikovanim polipurinskim nizom
|
|
WO2009132058A2
(en)
|
2008-04-25 |
2009-10-29 |
Zymogenetics, Inc. |
Levels of bcma protein expression on b cells and use in diagnostic methods
|
|
US8003335B2
(en)
|
2008-04-30 |
2011-08-23 |
Universite Paris-SUD11 |
Levels of APRIL in serum and use in diagnostic methods
|
|
AU2009241442B2
(en)
|
2008-05-01 |
2014-11-27 |
Zymogenetics, Inc. |
Levels of BLyS/ APRIL heterotrimers in serum and use in diagnostic methods
|
|
EP2540740B1
(en)
|
2008-06-17 |
2014-09-10 |
Apogenix GmbH |
Multimeric TNF receptors
|
|
WO2010098788A2
(en)
|
2008-08-25 |
2010-09-02 |
Amplimmune, Inc. |
Pd-i antagonists and methods for treating infectious disease
|
|
AU2009333580B2
(en)
|
2008-12-09 |
2016-07-07 |
Genentech, Inc. |
Anti-PD-L1 antibodies and their use to enhance T-cell function
|
|
WO2010093993A2
(en)
|
2009-02-12 |
2010-08-19 |
Human Genome Sciences, Inc. |
Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
|
|
EP2435477A1
(en)
|
2009-05-28 |
2012-04-04 |
Glaxo Group Limited |
Antigen-binding proteins
|
|
WO2011109280A1
(en)
|
2010-03-05 |
2011-09-09 |
Lerner Research Institute |
Methods and compositions to treat immune-mediated disorders
|
|
CN101851278B
(zh)
|
2010-05-26 |
2013-03-13 |
石药集团中奇制药技术（石家庄）有限公司 |
B细胞激活因子拮抗剂及其制备方法与用途
|
|
US20110311548A1
(en)
|
2010-06-18 |
2011-12-22 |
Human Genome Sciences, Inc. |
Use of b lymphocyte stimulator protein antagonists to treat asthma and other allergic and inflammatory conditions of the respiratory system
|
|
US20130295672A1
(en)
|
2010-09-10 |
2013-11-07 |
Consejo Superior De Investigaciones Científicas |
Stem cell culture media and methods
|
|
CN102085368B
(zh)
|
2011-01-19 |
2013-06-12 |
烟台荣昌生物工程有限公司 |
优化的TACI-Fc融合蛋白用于制备治疗系统性红斑狼疮药物的应用
|
|
EP2686345B1
(en)
|
2011-03-16 |
2018-04-25 |
Amgen Inc. |
Fc variants
|
|
WO2012141984A1
(en)
|
2011-04-08 |
2012-10-18 |
Immune Design Corp. |
Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
|
|
RS55609B1
(sr)
|
2011-04-13 |
2017-06-30 |
Bristol Myers Squibb Co |
Fc fuzioni proteini koji sadrže nove linkere ili aranžmane
|
|
WO2012149364A1
(en)
|
2011-04-28 |
2012-11-01 |
Diamond Don J |
Tumor associated vaccines and compositions for disrupting tumor-derived immunosuppression for use in combination cancer immunotherapy
|
|
WO2013041029A1
(en)
*
|
2011-09-23 |
2013-03-28 |
Igenimed Pharmaceuticals Inc. |
Novel soluble ctla4 variants
|
|
TWI476001B
(zh)
|
2011-12-26 |
2015-03-11 |
Ind Tech Res Inst |
三倍體Ｆｃ融合蛋白及其用途
|
|
CN117462693A
(zh)
|
2012-02-27 |
2024-01-30 |
阿穆尼克斯运营公司 |
Xten缀合组合物和制造其的方法
|
|
CN102585016B
(zh)
*
|
2012-03-06 |
2014-06-04 |
江苏健德生物药业有限公司 |
一种可同时抑制t、b淋巴细胞功能的免疫融合蛋白、其制备方法及其应用
|
|
PT2831095T
(pt)
|
2012-03-30 |
2019-01-30 |
Immune Design Corp |
Partículas de vectores lentivirais com melhor eficácia de transdução de células que expressam dc-sign
|
|
MX2014014951A
(es)
|
2012-06-06 |
2015-03-13 |
Oncomed Pharm Inc |
Agentes aglutinantes que modulan la trayectoria hippo y sus usos.
|
|
CN103232542B
(zh)
*
|
2013-02-01 |
2015-05-13 |
殷勇 |
一种双靶标嵌合蛋白
|
|
EP3744728A1
(en)
|
2013-02-12 |
2020-12-02 |
Bristol-Myers Squibb Company |
Tangential flow filtration based protein refolding methods
|
|
ES2870802T3
(es)
|
2013-02-12 |
2021-10-27 |
Bristol Myers Squibb Co |
Métodos de replegado de proteínas a elevado pH
|
|
HK1219740A1
(zh)
|
2013-03-15 |
2017-04-13 |
Biogen Ma Inc. |
使用抗αVβ5抗体治疗和预防急性肾损伤
|
|
RU2727639C2
(ru)
|
2014-01-15 |
2020-07-22 |
Ф.Хоффманн-Ля Рош Аг |
Варианты fc-области с модифицированной способностью связываться с fcrn и с сохраненной способностью связываться с белком а
|
|
US10562954B2
(en)
*
|
2014-05-12 |
2020-02-18 |
Shanghai Kanda Biotechnology Co., Ltd. |
Fusion protein inhibiting TACI-BAFF complex formation and preparation method therefor and use thereof
|
|
WO2015181343A2
(en)
|
2014-05-30 |
2015-12-03 |
Ventana Medical Systems, Inc. |
Multiplex assay for improved scoring of tumor tissues stained for pd-l1
|
|
EP3169352A1
(en)
|
2014-07-15 |
2017-05-24 |
Immune Design Corp. |
Prime-boost regimens with a tlr4 agonist adjuvant and a lentiviral vector
|
|
WO2016023001A1
(en)
|
2014-08-08 |
2016-02-11 |
The Board Of Trustees Of The Leland Stanford Junior University |
Multispecific high affinity pd-1 agents and methods of use
|
|
NL2014108B1
(en)
|
2015-01-09 |
2016-09-30 |
Aduro Biotech Holdings Europe B V |
Altered april binding antibodies.
|
|
TWI833684B
(zh)
|
2015-06-25 |
2024-03-01 |
美商生物細胞基因治療有限公司 |
嵌合抗原受體（ｃａｒ）、組合物及其使用方法
|
|
EP3322801A1
(en)
|
2015-07-15 |
2018-05-23 |
Juno Therapeutics, Inc. |
Engineered cells for adoptive cell therapy
|
|
WO2017019846A1
(en)
|
2015-07-30 |
2017-02-02 |
Macrogenics, Inc. |
Pd-1-binding molecules and methods use thereof
|
|
DK3380522T5
(da)
|
2015-11-25 |
2024-09-30 |
Visterra Inc |
Antistofmolekyler til april og anvendelser deraf
|
|
US10954301B2
(en)
*
|
2015-12-14 |
2021-03-23 |
Macrogenics, Inc. |
Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereof
|
|
ES2898329T3
(es)
|
2016-01-12 |
2022-03-07 |
Oncotracker Inc |
Métodos mejorados para supervisar el estado inmunitario de un sujeto
|
|
EP4706777A2
(en)
|
2016-04-15 |
2026-03-11 |
Alpine Immune Sciences, Inc. |
Cd80 variant immunomodulatory proteins and uses thereof
|
|
IL262365B2
(en)
|
2016-04-15 |
2024-11-01 |
Alpine Immune Sciences Inc |
Immunomodulatory proteins ICOS ligand variants and uses thereof
|
|
EP3452101A2
(en)
|
2016-05-04 |
2019-03-13 |
CureVac AG |
Rna encoding a therapeutic protein
|
|
US20200326339A1
(en)
|
2016-05-16 |
2020-10-15 |
James Richard BERENSON |
Improved methods for monitoring immune status of a subject
|
|
JP7114490B2
(ja)
|
2016-06-24 |
2022-08-08 |
アイセル・ジーン・セラピューティクス・エルエルシー |
キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法
|
|
CN110088127A
(zh)
|
2016-07-28 |
2019-08-02 |
高山免疫科学股份有限公司 |
Cd155变体免疫调节蛋白及其用途
|
|
US11834490B2
(en)
|
2016-07-28 |
2023-12-05 |
Alpine Immune Sciences, Inc. |
CD112 variant immunomodulatory proteins and uses thereof
|
|
CA3040296A1
(en)
|
2016-10-20 |
2018-04-26 |
Alpine Immune Sciences, Inc. |
Secretable variant immunomodulatory proteins and engineered cell therapy
|
|
PT3596116T
(pt)
|
2017-03-16 |
2023-12-04 |
Alpine Immune Sciences Inc |
Proteínas imunomoduladoras de pd-l1 variante e suas utilizações
|
|
JP2020511144A
(ja)
|
2017-03-16 |
2020-04-16 |
アルパイン イミューン サイエンシズ インコーポレイテッド |
Ｐｄ−ｌ２バリアント免疫調節タンパク質及びその使用
|
|
EP3596114A2
(en)
|
2017-03-16 |
2020-01-22 |
Alpine Immune Sciences, Inc. |
Cd80 variant immunomodulatory proteins and uses thereof
|
|
EP3642243A4
(en)
|
2017-06-20 |
2021-04-28 |
Dana-Farber Cancer Institute, Inc. |
METHOD OF MODULATING REGULATORY T-CELLS, REGULATORY B-CELLS AND IMMUNE RESPONSIBILITIES USING MODULATORS OF APRIL-TACI INTERACTION
|
|
CN111655280B
(zh)
|
2017-09-01 |
2025-01-14 |
达纳-法伯癌症研究所股份有限公司 |
用于治疗癌症的bcma和taci抗原特异的免疫原性肽
|
|
KR102813968B1
(ko)
|
2017-10-10 |
2025-05-29 |
알파인 이뮨 사이언시즈, 인코포레이티드 |
Ctla-4 변이체 면역조절 단백질 및 이의 용도
|
|
SMT202600062T1
(it)
|
2017-10-18 |
2026-03-09 |
Alpine Immune Sciences Inc |
Proteine immunomodulatrici del ligando di icos variante e composizioni e metodi correlati
|
|
GB201720426D0
(en)
|
2017-12-07 |
2018-01-24 |
Hummingbird Bioscience Pte Ltd |
CD47 and BCMA antigen-binding molecules
|
|
SG11202006148UA
(en)
|
2018-01-03 |
2020-07-29 |
Alpine Immune Sciences Inc |
Multi-domain immunomodulatory proteins and methods of use thereof
|
|
WO2019169290A1
(en)
|
2018-03-02 |
2019-09-06 |
Allogene Therapeutics, Inc. |
Inducible chimeric cytokine receptors
|
|
US20210238295A1
(en)
|
2018-04-26 |
2021-08-05 |
University Of Virginia Patent Foundation |
Compositions and methods for treating abdominal aortic aneurysm
|
|
CN110522908A
(zh)
|
2018-05-25 |
2019-12-03 |
荣昌生物制药（烟台）有限公司 |
TACI-Fc融合蛋白用于制备治疗视神经脊髓炎谱系疾病和多发性硬化之药物中的应用
|
|
US12065476B2
(en)
|
2018-06-15 |
2024-08-20 |
Alpine Immune Sciences, Inc. |
PD-1 variant immunomodulatory proteins and uses thereof
|
|
WO2020028572A2
(en)
|
2018-08-01 |
2020-02-06 |
Unum Therapeutics Inc. |
ANTIBODY-COUPLED T CELL RECEPTORS (ACTRs) IN COMBINATION WITH TRANS CO-STIMULATORY MOLECULES AND THERAPEUTIC USES THEREOF
|
|
WO2020047329A1
(en)
|
2018-08-29 |
2020-03-05 |
Shattuck Labs, Inc. |
Chimeric proteins comprising extracellular domains and uses thereof
|
|
AU2019345151B2
(en)
|
2018-09-19 |
2025-04-17 |
Alpine Immune Sciences, Inc. |
Methods and uses of variant CD80 fusion proteins and related constructs
|
|
WO2020097403A1
(en)
|
2018-11-08 |
2020-05-14 |
Juno Therapeutics, Inc. |
Methods and combinations for treatment and t cell modulation
|
|
WO2020113141A2
(en)
|
2018-11-30 |
2020-06-04 |
Alpine Immune Sciences, Inc. |
Cd86 variant immunomodulatory proteins and uses thereof
|
|
EP4438054A3
(en)
|
2019-04-17 |
2025-01-08 |
Alpine Immune Sciences, Inc. |
Methods and uses of variant icos ligand (icosl) fusion proteins
|
|
CN114728040A
(zh)
|
2019-06-14 |
2022-07-08 |
科优基因公司 |
新型白介素-2变体及其双功能融合分子
|
|
EP4056232A4
(en)
|
2019-09-13 |
2023-09-13 |
Kyowa Kirin Co., Ltd. |
DCR3 VARIANT
|
|
AU2020401160B2
(en)
|
2019-12-10 |
2024-11-14 |
Remegen Co., Ltd. |
Pharmaceutical TACI-Fc fusion protein formulation
|
|
KR20220034742A
(ko)
|
2019-12-24 |
2022-03-18 |
레메젠 코, 리미티드 |
Taci-fc 융합 단백질 및 그 용도
|
|
JP7748393B2
(ja)
|
2020-05-08 |
2025-10-02 |
アルパイン イミューン サイエンシズ インコーポレイテッド |
Ａｐｒｉｌおよびｂａｆｆ阻害免疫調節タンパク質、ならびにその使用方法
|
|
AU2021285813A1
(en)
|
2020-06-02 |
2023-02-02 |
Ares Trading S.A. |
Methods related to the treatment of IGA nephropathy
|
|
KR20240019124A
(ko)
|
2021-05-07 |
2024-02-14 |
알파인 이뮨 사이언시즈, 인코포레이티드 |
Taci-fc 융합 면역조절 단백질의 투여 및 치료 방법
|
|
US20240002468A1
(en)
|
2021-08-10 |
2024-01-04 |
Remegen Co., Ltd. |
Method for treating iga nephropathy with taci-fc fusion protein
|
|
AU2022358137B2
(en)
|
2021-09-30 |
2026-02-12 |
Remegen Co., Ltd. |
Method for treating sjogren’s syndrome using taci-fc fusion protein
|
|
IL317055A
(en)
|
2022-06-08 |
2025-01-01 |
Remegen Co Ltd |
METHOD FOR TREATING MYASTHENIA GRAVIS WITH TACI-FC FUSION PROTEIN
|
|
WO2024077018A2
(en)
|
2022-10-04 |
2024-04-11 |
Alpine Immune Sciences, Inc. |
Methods and uses of taci-fc fusion immunomodulatory protein
|